Eine Rakete, die aus einem Laptop hervorgeht als Symbol für Start-up-Ideen (Symbolbild).
Mittwoch, 19.07.2017 10:00 von GlobeNewswire | Aufrufe: 114

Orion Corporation's financial reporting and Annual General Meeting in 2018

Eine Rakete, die aus einem Laptop hervorgeht als Symbol für Start-up-Ideen (Symbolbild). © peshkov / iStock / Getty Images Plus / Getty Images

   

ORION CORPORATION     STOCK EXCHANGE  RELEASE   19 JULY 2017 at 11.00 A.M. EEST


Orion Corporation's financial reporting and Annual General Meeting in 2018 
 

Orion Corporation will publish its Financial Statement  Release 2017 on Wednesday,  7 February 2018.
The publication dates of the Interim Reports and the Half-Year Financial Report in 2018 are as follows:

Interim Report January-March 2018 
Half-Year Financial Report January-June 2018 
Interim Report January-September 2018 
Tuesday , 24 April 2018
Wednesday, 18 July 2018
Wednesday, 24 October 2018


 The Financial Statements and the report of the Board of Directors for 2017 will be published on the Company's website at the latest in week 9/2018.

The Annual General Meeting is planned to be held on Tuesday, 20 March 2018 in Helsinki.

Orion's financial reports and related presentation material are available on the Group's website at http://www.orion.fi/investors promptly after the publishing. The website also provides a possibility to register on Orion's mailing lists for releases. 

  
Orion Corporation

Timo Lappalainen
President and CEO
  Olli Huotari
SVP, Corporate Functions
 

Contact person:                                                                        
Lilli Riikonen, Communications Manager,  tel. +358 10 426 2319

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2016 amounted to EUR 1,074 million and the company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq Helsinki. Founded in 1917, Orion celebrates its centennial anniversary in 2017.


ARIVA.DE Börsen-Geflüster

Kurse

33,08
-0,03%
Orion Corp B Realtime-Chart



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orion Oyj via Globenewswire

Werbung

Mehr Nachrichten zur Orion Corp B Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Andere Nutzer interessierten sich auch für folgende News